...
首页> 外文期刊>The Indian journal of tuberculosis >IS IT WORTH TREATING CATEGORY I FAILURE PATIENTS WITH CATEGORY II REGIMEN?
【24h】

IS IT WORTH TREATING CATEGORY I FAILURE PATIENTS WITH CATEGORY II REGIMEN?

机译:是否可以使类别II类别的患者失败的治疗类别值得?

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Very little information is available on the drug susceptibility profile among patients who are treated with standardized short-course chemotherapy regimens under programme conditions.Methods: Sputum samples were collected from new sputum smear-positive patients declared 'failure' after treatment with Category I regimen under tuberculosis control programme using DOTS strategy from a rural area of Tamil Nadu.Results: Of 1463 patients started on Category I regimen between May 1999 and December 2002, 74 cases were declared as 'failures' (smear positive at 5/6 months of treatment). We collected sputum samples from 60 (81%) of 74 'failures' and 27% (16 of 60) of them were culture-negative for Mtuberculosis and 17% (10 of 60) had organisms resistant to Isoniazid and Rifampicin (MDR TB).Conclusion: Based on the drug susceptibility profile at the time of 'failure', treating Category I 'failures' with Category II regimen with close monitoring appears to be justified.
机译:背景:在计划条件下接受标准短程化疗方案治疗的患者中,关于药物敏感性概况的信息很少。方法:从I类治疗后被宣布为``失败''的新痰涂片阳性患者中收集痰标本结果:在1999年5月至2002年12月间,从泰米尔纳德邦农村地区采用DOTS策略进行的结核病控制计划中,有1463例患者开始接受I类治疗,其中74例被宣布为“失败”(在5/6个月的涂片阳性)。治疗)。我们从74例“失败”患者中的60例(占81%)中收集了痰标本,其中27%(60例中有16例)对结核病培养阴性,而17%(60例中有10例)对异烟肼和利福平(MDR TB)有抗药性结论:基于“失败”时的药物敏感性概况,采用II类方案并密切监视治疗I类“失败”似乎是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号